Health bosses issue urgent warning over peptide Retatrutide linked to liver damage
Health officials warned that the experimental peptide Retatrutide is linked to acute liver damage after six cases emerged in Victoria since January. The Therapeutic Goods Administration urged people to avoid the unapproved product, which is not sold in pharmacies and may pose serious health risks. Investigations into the product's safety are ongoing.
Summary by OZbrief Editorial · The West Australian · Source
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 19 Jun 2026, 09:20 UTC · Updated 19 Jun 2026, 09:30 UTC
Summary by OZbrief Editorial. Original report: The West Australian. Editorial policy · Corrections
Related stories
- The many questions that Hanson needs to answer
- AI-powered drones could patrol Sydney beaches to prevent shark attacks
- ‘Absolute disrespect’: Bulldozers at the gate as fight over river steps up
- Bathurst champ fumes over 'dangerous' move
- Campbelltown curse continues as Tigers go down to Dolphins
- Electoral reform and education essential to eliminate populist politics
Trending
- Royal Ascot 2026: horse racing updates from day five – live
- ‘Horrific’: Train delays after man dies in fuel tanker rollover in Darnum
- JLR at risk of battery supply delays after Somerset factory turmoil
- Andy Burnham wins Makerfield byelection, emerges as Labour leadership contender
- Tips and race-by-race guide for Wagga Wagga on Sunday
- Injury woes mount for Tigers